Lantheus Medical Imaging Extends Contract With NTP Radioisotopes to Ensure Robust Supply of LEU-Produced Molybdenum-99

NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Medical Imaging, Inc. (Lantheus or the Company) and two world leaders in producing medical isotopes have agreed to work together to help ensure supplies of potentially life-saving nuclear medicine using molybdenum-99 (Mo-99) sourced from Low Enriched Uranium (LEU).

Back to news